Brooks Laboratories Approves 1:1 Demerger Of 96 Percent Business Into Abridge

Board approved demerger of Manufacturing Business, 96.66% of FY26 turnover, into wholly owned Abridge Speciality for 1:1 listed shares; Abridge to be renamed Brooks, residual Xuri. First split of profitable manufacturing from tiny loss-making trading; aligns each platform with promoter groups for succession; needs exchange, SEBI, NCLT nods, ~16 months to listing. Shareholders keep mirror 1:1 holding in both entities with no cash or dilution; execution hinges on approval chain; JV allocation and interplay with pending BSL-OneSource scheme undisclosed.